{
  "id": "clinical#risk_safety_efbcbd76",
  "content": "dividuals recovering within 1 week and nearly all within 30 days.\nThe duration may be prolonged when long-acting antipsychotics are\nimplicated. There have been reports of individuals in whom residual\n348 Medication-Induced Movement Disorders\nneurological signs persisted for weeks after the acute hypermetabolic\nsymptoms resolved. Total resolution of symptoms can be obtained in\nmost cases of neuroleptic malignant syndrome; however, fatality\nrates of 10%–20% have been reported when the disorder is not recog-\nnized. Although many individuals do not experience a recurrence of\nneuroleptic malignant syndrome when rechallenged with antipsy-\nchotic medication, some do, especially when antipsychotics are rein-\nstituted soon after an episode.\nRisk and Prognostic Factors\nNeuroleptic malignant syndrome is a potential risk in any individual\nafter antipsychotic drug administration. It is not specific to any neu-\nropsychiatric diagnosis and may occur in individuals without a di-\nagnosable mental disorder who receive dopamine antagonists.\nClinical, systemic, and metabolic factors associated with a height-\nened risk of neuroleptic malignant syndrome include agitation,\nexhaustion, dehydration, and iron deficiency. A prior episode asso-\nciated with antipsychotics has been described in 15%–20% of index\ncases, suggesting underlying vulnerability in some patients; how-\never, genetic findings based on neurotransmitter receptor polymor-",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety dividuals recovering within 1 week and nearly all within 30 days.\nThe duration may be prolonged when long-acting antipsychotics are\nimplicated. There have been reports of individuals in whom residual\n348 Medication-Induced Movement Disorders\nneurological signs persisted for weeks after the acute hypermetabolic\nsymptoms resolved. Total resolution of symptoms can be obtained in\nmost cases of neuroleptic malignant syndrome; however, fatality\nrates of 10%–20% have been reported when the disorder is not recog-\nnized. Although many individuals do not experience a recurrence of\nneuroleptic malignant syndrome when rechallenged with antipsy-\nchotic medication, some do, especially when antipsychotics are rein-\nstituted soon after an episode.\nRisk and Prognostic Factors\nNeuroleptic malignant syndrome is a potential risk in any individual\nafter antipsychotic drug administration. It is not specific to any neu-\nropsychiatric diagnosis and may occur in individuals without a di-\nagnosable mental disorder who receive dopamine antagonists.\nClinical, systemic, and metabolic factors associated with a height-\nened risk of neuroleptic malignant syndrome include agitation,\nexhaustion, dehydration, and iron deficiency. A prior episode asso-\nciated with antipsychotics has been described in 15%–20% of index\ncases, suggesting underlying vulnerability in some patients; how-\never, genetic findings based on neurotransmitter receptor polymor- Dividuals recovering within 1 week and nearly all within 30 days. the duration may be prolonged when long-acting antipsychotics are\nimplicated."
}